首页> 外文学位 >A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin

【24h】

A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究

获取原文

获取原文并翻译 | 示例

页面导航

著录项
相似文献
相关主题

著录项

作者
Venkatramani, Rajkumar.;
展开▼
作者单位

University of Southern California.;

展开▼
授予单位 University of Southern California.;
学科
学位 M.S.
年度 2010
页码 86 p.
总页数 86
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-17 11:55:58

相似文献

外文文献
中文文献

1. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors [J] . WagnerL., TurpinB., NagarajanR., Pediatric blood & cancer . 2013,第9期

机译：长春新碱，口服伊立替康和替莫唑胺（VOIT方案）联合贝伐单抗在小儿复发性实体瘤或脑瘤患者中的初步研究
2. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors [J] . OkadaK., YamasakiK., TanakaC., Japanese journal of clinical oncology. . 2013,第11期

机译：贝伐单抗联合伊立替康治疗儿童复发/难治性实体瘤的I期研究
3. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. [J] . McGregor LM, Stewart CF, Crews KR, Pediatric blood & cancer . 2012,第3期

机译：口服头孢泊肟静脉注射依立替康的剂量递增：I期研究在顽固性实体瘤的儿科患者中进行。
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A Phase I Study of Vincristine Irinotecan Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors [O] . Rajkumar Venkatramani, Marcio Malogolowkin, Tom B. Davidson, -1

机译：长春新碱伊立替康替莫唑胺和贝伐单抗（Vitb）在小儿实体瘤复发患者中的I期研究
6. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. [O] . Rajkumar Venkatramani, Marcio Malogolowkin, Tom B Davidson, 2013

机译：I期研究长春新碱，伊立替康，替莫唑胺和贝伐单抗（vitb）治疗复发性实体瘤的儿科患者。

A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin

著录项

相似文献

相关主题

期刊订阅